



D		Value Indicators:	EUR	Warburg ESG Risk Score:	3.7	Description:	
Buy		DCF:	234.69	ESG Score (MSCI based):	4.0	Technology-based financial	services
EUR 235.00				Balance Sheet Score: Market Liquidity Score:	4.0 3.0	provider	
		Market Snapshot:	EUR m	Shareholders:		Key Figures (WRe):	2023e
		Market cap:	1,126.55	Freefloat	61.70 %	Beta:	1.2
Price	EUR 170.00	No. of shares (m):	6.63	Revenia (Ronald Slabke)	34.60 %	Price / Book:	3.4 x
Upside	38.2 %	EV:	1,227.98	Treasury shares	3.70 %	Equity Ratio:	51 %
		Freefloat MC:	695.08			Net Fin. Debt / EBITDA:	2.2 x
		Ø Trad. Vol. (30d):	1.98 m			Net Debt / EBITDA:	2.2 x

Perfectly positioned for market recovery

Meeting Highlights


- CEO Slabke stated that Q4 should have constituted the low point of the German mortgage market. In Q1 and Q2 the market showed a slight upward tendency, yet not at the pace the company would have hoped. However, he expects the market to continue its recovery, which should, at some point in time, pick up the pace as the pressure in the rental market increases and people start to accept the current prices in the higher interest-rate environment.
- The implemented cost-savings programme is progressing according to plan. However, once the market starts to normalize, about one-third of the costs saved will presumably return. Going forward, cost increases will most likely be driven by general wage inflation and increasing headcount.
- Last week, Deutsche Bank announced the restructuring of its mortgage business and the harmonization of business processes within the unit. In this context, Hypoport managed to become the provider of mortgage software for the whole group going forward. Ultimately, this will result in an increased mortgage volume on the platform as each standardized mortgage sold by Deutsche Bank will be handled by Europace. While this will result in a volume effect on the platform, the signalling effect from the migration of the largest German bank to Europace should not be underestimated
- Hypoport introduced a new pricing scheme for independent mortgage brokers at Europace. Formerly, the pricing was at 1bps discounted to today per year of fixed-interest rates. On average, this resulted in a fee of about 10bps on the financing volume. As of July, the 1bps will remain untouched but the discount factor will be removed. Consequently, this should result in a price increase of about 20% on the volume brokered by independent mortgage agents. We expect Hypoport currently generates about 40-50% of the volume on Europace via such agents.

Conclusion

- The market recovery that has just started, according to Hypoport, should help the company to show improving results over the next quarters.
- Furthermore, the deal with Deutsche Bank should ensure a sustained outperformance of the underlying mortgage market.
- Finally, the price increases for mortgage volume brokered by independent agents should help Hypoport to ensure the achievement of its 2023 quidance.
- Overall, the investment case remains highly market-driven but it appears that all market participants agree on a recovery, sooner or later, in the market for real estate and therefore mortgages. With Hypoport remaining perfectly positioned to benefit from a recovery, the share continues to be attractively valued.

		FY End: 31.12.	CAGR							
250 -		in EUR m	(22-25e)	2019	2020	2021	2022	2023e	2024e	2025e
225 - m mmmur	mar	Sales	6.7 %	337.24	387.73	446.35	455.50	433.62	490.64	553.72
200 - WY M JWW		Change Sales yoy		26.8 %	15.0 %	15.1 %	2.1 %	-4.8 %	13.1 %	12.9 %
175 - W W W		Gross profit margin		58.9 %	59.7 %	61.2 %	58.0 %	58.2 %	59.3 %	60.7 %
175 -	1	EBITDA	19.2 %	52.22	63.85	77.10	51.90	46.60	63.41	87.97
150 - h Min	m	Margin		15.5 %	16.5 %	17.3 %	11.4 %	10.7 %	12.9 %	15.9 %
125 -		EBIT	29.9 %	33.01	36.24	47.68	24.71	20.72	34.21	54.12
100 -		Margin		9.8 %	9.3 %	10.7 %	5.4 %	4.8 %	7.0 %	9.8 %
n in		Net income	31.9 %	24.40	27.27	30.16	17.67	14.57	25.06	40.55
75 - 07/22 09/22 11/22 01/23 03/23 0)5/23	EPS	29.3 %	3.90	4.36	4.83	2.83	2.20	3.78	6.12
		EPS adj.	29.3 %	3.90	4.36	4.83	2.83	2.20	3.78	6.12
- Hypoport SE - SDAX (normalised)		DPS	-	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Rel. Performance vs SDAX:		Dividend Yield		n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
	22.7 %	FCFPS		3.07	1.59	4.35	0.12	-0.46	0.76	3.73
		FCF / Market cap		1.4 %	0.4 %	0.9 %	0.0 %	-0.3 %	0.4 %	3.3 %
	70.6 %	EV / Sales		4.4 x	6.9 x	7.5 x	3.5 x	2.8 x	2.5 x	1.5 x
Year to date:	63.0 %	EV / EBITDA		28.5 x	41.7 x	43.1 x	30.4 x	26.4 x	19.3 x	9.3 x
Trailing 12 months:	-25.7 %	EV / EBIT		45.0 x	73.5 x	69.8 x	63.8 x	59.3 x	35.7 x	15.1 x
		P/E		57.2 x	92.0 x	105.3 x	83.6 x	77.3 x	45.0 x	18.4 x
Company events:		P / E adj.		57.2 x	92.0 x	105.3 x	83.6 x	77.3 x	45.0 x	18.4 x
14.08.23	Q2	FCF Potential Yield		3.0 %	2.2 %	1.9 %	3.0 %	3.5 %	4.6 %	9.4 %
13.11.23	Q3	Net Debt		90.89	156.89	149.11	98.37	101.43	96.37	71.67
		ROCE (NOPAT)		10.9 %	9.3 %	8.4 %	4.7 %	3.8 %	6.0 %	9.1 %
		Guidance: 2	2023: Revenu	e up to -10%	; EBIT up to	-30%				






Company Background

- The company, founded in 1999, is specialised as a property financing intermediary and is expanding its value chain towards the insurance and real estate sectors
- With EUROPACE, Hypoport operates the largest German online B2B platform for property financing and similar products
- Under the Dr. Klein brand, Hypoport operates a franchise system of stationary advisors for private customers
- Hypoport is also in a leading position in the area of institutional property financing (also under the Dr. Klein brand)
- An advanced level of technology is shown in all segments (fintech)

Competitive Quality

- The online B2B marketplace for property financing (EUROPACE) is the largest of its kind in Germany
- As the number of affiliated suppliers is decisive for marketplaces of this type, this forms a central competitive advantage and a considerable market entry barrier for third parties.
- The Dr. Klein business segments (private clients) benefits from market access over EUROPACE but also from the many years of experience in the area of property financing
- Most importantly however Dr. Klein is strongly focused on property financing and neutral (with offers from every provider). Other financial
 sales teams or retail banks normally cannot afford both.
- The new platform businesses insurance platform and real estate platform should strongly benefit of the market-leading credit platform and the excellent track record of the company.





DCF model														
	Detaile	d forecas	t period				1	Fransitior	nal period	1				Term. Value
Figures in EUR m	2023e	2024e	2025e	2026e	2027e	2028e	2029e	2030e	2031e	2032e	2033e	2034e	2035e	
Sales	423.77	479.49	541.14	604.88	669.42	736.36	810.00	891.00	971.19	1,039.17	1,080.74	1,113.16	1,135.43	
Sales change	-7.0 %	13.1 %	12.9 %	11.8 %	10.7 %	10.0 %	10.0 %	10.0 %	9.0 %	7.0 %	4.0 %	3.0 %	2.0 %	1.5 %
EBIT	20.72	34.21	54.12	72.47	96.57	132.55	162.00	196.02	233.09	259.79	270.19	278.29	283.86	
EBIT-margin	4.7 %	6.9 %	9.7 %	12.0 %	14.4 %	18.0 %	20.0 %	22.0 %	24.0 %	25.0 %	25.0 %	25.0 %	25.0 %	
Tax rate (EBT)	22.2 %	22.2 %	22.2 %	22.0 %	22.0 %	22.0 %	22.0 %	22.0 %	22.0 %	22.0 %	22.0 %	22.0 %	22.0 %	
NOPAT	16.12	26.62	42.11	56.53	75.32	103.39	126.36	152.90	181.81	202.64	210.74	217.07	221.41	
Depreciation	25.88	29.20	33.85	33.27	33.47	33.14	32.40	35.64	38.85	41.57	43.23	44.53	45.42	
in % of Sales	6.1 %	6.1 %	6.3 %	5.5 %	5.0 %	4.5 %	4.0 %	4.0 %	4.0 %	4.0 %	4.0 %	4.0 %	4.0 %	
Changes in provisions	0.00	0.00	0.00	-0.01	0.06	0.07	0.07	0.08	0.08	0.07	0.04	0.03	0.02	
Change in Liquidity from														
- Working Capital	-1.50	4.20	4.70	3.97	4.84	5.02	5.52	6.08	6.01	5.10	3.12	2.43	1.67	
- Capex	45.00	45.00	45.00	42.34	40.17	36.82	32.40	35.64	38.85	41.57	43.23	44.53	45.42	
Capex in % of Sales	10.6 %	9.4 %	8.3 %	7.0 %	6.0 %	5.0 %	4.0 %	4.0 %	4.0 %	4.0 %	4.0 %	4.0 %	4.0 %	
- Other	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
Free Cash Flow (WACC Model)	-1.50	6.62	26.26	43.48	63.85	94.75	120.91	146.90	175.87	197.61	207.67	214.67	219.76	223
PV of FCF	-1.41	5.68	20.65	31.33	42.16	57.33	67.04	74.64	81.88	84.30	81.18	76.90	72.14	961
share of PVs		1.51 %						40.4	1 %					58.08 %
Model parameter							Valuat	ion (m)						
Derivation of WACC:			Derivation	of Beta:				t values 2	035e	-	94			
	0.00.0/					4.00		al Value			61 05			
Debt ratio Cost of debt (after tax)	0.00 % 2.3 %		Financial S Liquidity (s	•		1.00 1.20		ial liabilitie n liabilities		1	85 1			
Market return	2.3 % 8.25 %		Cyclicality	nale)		1.20	Hybrid				0			
Risk free rate	0.25 % 2.75 %		Transpare	ncv		1.00		y interest			2			
	2.10 /0		Others	,		1.30		val. of inv	estments		0			
							Liquidit				88	No. of sha	ares (m)	6.6
								.,					. ,	

Sensitivity Value per Share (EUR)

9.13 %

Beta

WACC

		Terminal C	Growth								Delta EBIT	-margin					
Beta	WACC	0.75 %	1.00 %	1.25 %	1.50 %	1.75 %	2.00 %	2.25 %	Beta	WACC	-1.5 pp	-1.0 pp	-0.5 pp	+0.0 pp	+0.5 pp	+1.0 pp	+1.5 pp
1.34	10.1 %	186.78	189.66	192.70	195.91	199.32	202.93	206.78	1.34	10.1 %	179.43	184.79	190.16	195.53	200.90	206.26	211.63
1.25	9.6 %	203.17	206.58	210.19	214.02	218.10	222.44	227.07	1.25	9.6 %	196.39	202.14	207.89	213.64	219.38	225.13	230.88
1.21	9.4 %	212.15	215.86	219.81	224.00	228.47	233.25	238.35	1.21	9.4 %	205.74	211.70	217.66	223.62	229.57	235.53	241.49
1.16	9.1 %	221.70	225.76	230.08	234.69	239.60	244.86	250.50	1.16	9.1 %	215.75	221.94	228.12	234.30	240.48	246.66	252.84
1.11	8.9 %	231.90	236.34	241.08	246.14	251.56	257.37	263.62	1.11	8.9 %	226.49	232.91	239.33	245.75	252.18	258.60	265.02
1.07	8.6 %	242.79	247.67	252.88	258.46	264.44	270.87	277.81	1.07	8.6 %	238.03	244.71	251.39	258.07	264.74	271.42	278.10
0.98	8.1 %	266.96	272.88	279.22	286.04	293.40	301.36	309.99	0.98	8.1 %	263.90	271.15	278.40	285.65	292.90	300.15	307.40

Equity Value

1,555

Value per share (EUR) 234.69

1.16

• The growth anticipated for Hypoport is based on robust business development in all segments

• Credit platform segment (EUROPACE) in particular offers systematic potential for economies of scale and margin growth

• On this basis we assume a positive long-term margin trend

- Based on a sophisticated regional dispersion of tax obligations a low tax rate is assumed long term.



Valuation							
	2019	2020	2021	2022	2023e	2024e	2025e
Price / Book	7.8 x	11.4 x	12.6 x	4.6 x	3.4 x	3.1 x	1.9 x
Book value per share ex intangibles	-11.24	-13.76	-11.38	-2.74	-2.57	-0.67	3.99
EV / Sales	4.4 x	6.9 x	7.5 x	3.5 x	2.8 x	2.5 x	1.5 x
EV / EBITDA	28.5 x	41.7 x	43.1 x	30.4 x	26.4 x	19.3 x	9.3 x
EV / EBIT	45.0 x	73.5 x	69.8 x	63.8 x	59.3 x	35.7 x	15.1 x
EV / EBIT adj.*	45.0 x	73.5 x	69.8 x	63.8 x	59.3 x	35.7 x	15.1 x
P / FCF	72.7 x	252.7 x	116.8 x	n.a.	n.a.	222.5 x	30.2 x
P/E	57.2 x	92.0 x	105.3 x	83.6 x	77.3 x	45.0 x	18.4 x
P / E adj.*	57.2 x	92.0 x	105.3 x	83.6 x	77.3 x	45.0 x	18.4 x
Dividend Yield	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
FCF Potential Yield (on market EV)	3.0 %	2.2 %	1.9 %	3.0 %	3.5 %	4.6 %	9.4 %
*Adjustments made for: -							

Consolidated profit & loss




In EUR m	2019	2020	2021	2022	2023e	2024e	2025e
Sales	337.24	387.73	446.35	455.50	433.62	490.64	553.72
Change Sales yoy	26.8 %	15.0 %	15.1 %	2.1 %	-4.8 %	13.1 %	12.9 %
Increase / decrease in inventory	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Own work capitalised	16.58	20.78	23.62	24.60	23.42	26.49	29.90
Total Sales	353.82	408.51	469.97	480.10	457.04	517.14	583.63
Material expenses	155.32	177.20	196.86	216.03	204.60	226.18	247.58
Gross profit	198.50	231.31	273.10	264.07	252.44	290.96	336.05
Gross profit margin	58.9 %	59.7 %	61.2 %	58.0 %	58.2 %	59.3 %	60.7 %
Personnel expenses	106.64	133.88	155.46	165.03	161.20	178.20	195.06
Other operating income	3.03	6.61	5.64	5.24	4.96	5.48	7.00
Other operating expenses	42.06	40.48	46.06	52.37	49.60	54.83	60.02
Unfrequent items	-0.62	0.28	-0.12	0.00	0.00	0.00	0.00
EBITDA	52.22	63.85	77.10	51.90	46.60	63.41	87.97
Margin	15.5 %	16.5 %	17.3 %	11.4 %	10.7 %	12.9 %	15.9 %
Depreciation of fixed assets	9.69	14.70	13.49	10.88	10.35	11.68	13.54
EBITA	42.52	49.15	63.61	41.03	36.25	51.73	74.43
Amortisation of intangible assets	9.52	12.92	15.93	16.32	15.53	17.52	20.31
Goodwill amortisation	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT	33.01	36.24	47.68	24.71	20.72	34.21	54.12
Margin	9.8 %	9.3 %	10.7 %	5.4 %	4.8 %	7.0 %	9.8 %
EBIT adj.	33.01	36.24	47.68	24.71	20.72	34.21	54.12
Interest income	0.51	0.23	0.16	0.80	0.80	0.80	0.80
Interest expenses	2.07	3.07	3.59	3.00	3.00	3.00	3.00
Other financial income (loss)	0.00	0.00	0.00	0.20	0.20	0.20	0.20
EBT	31.44	33.40	44.25	22.71	18.72	32.21	52.12
Margin	9.3 %	8.6 %	9.9 %	5.0 %	4.3 %	6.6 %	9.4 %
Total taxes	7.04	5.54	13.68	5.04	4.16	7.15	11.57
Net income from continuing operations	24.40	27.86	30.58	17.67	14.57	25.06	40.55
Income from discontinued operations (net of tax)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net income before minorities	24.40	27.86	30.58	17.67	14.57	25.06	40.55
Minority interest	0.00	0.59	0.41	0.00	0.00	0.00	0.00
Net income	24.40	27.27	30.16	17.67	14.57	25.06	40.55
Margin	7.2 %	7.0 %	6.8 %	3.9 %	3.4 %	5.1 %	7.3 %
Number of shares, average	6.25	6.25	6.25	6.25	6.63	6.63	6.63
EPS	3.90	4.36	4.83	2.83	2.20	3.78	6.12
EPS adj.	3.90	4.36	4.83	2.83	2.20	3.78	6.12
*Adjustments made for:							

Guidance: 2023: Revenue up to -10%; EBIT up to -30%


Financial Ratios

	2019	2020	2021	2022	2023e	2024e	2025e
Total Operating Costs / Sales	89.2 %	89.0 %	88.0 %	94.0 %	94.7 %	92.5 %	89.5 %
Operating Leverage	0.5 x	0.7 x	2.1 x	-23.5 x	3.4 x	4.9 x	4.5 x
EBITDA / Interest expenses	25.2 x	20.8 x	21.5 x	17.3 x	15.5 x	21.1 x	29.3 x
Tax rate (EBT)	22.4 %	16.6 %	30.9 %	22.2 %	22.2 %	22.2 %	22.2 %
Dividend Payout Ratio	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %
Sales per Employee	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.






Operating Performance in %



Performance per Share



Comment Pu


5



Consolidated balance sheet							
In EUR m	2019	2020	2021	2022	2023e	2024e	2025e
Assets							
Goodwill and other intangible assets	248.24	306.42	322.89	336.57	351.05	363.53	373.22
thereof other intangible assets	14.64	24.06	27.74	41.42	55.89	68.37	78.06
thereof Goodwill	186.40	221.96	222.41	222.41	222.41	222.41	222.41
Property, plant and equipment	34.99	97.66	101.89	106.01	110.66	113.98	115.44
Financial assets	0.19	0.40	0.78	0.78	0.78	0.78	0.78
Other long-term assets	14.14	28.96	28.30	28.30	28.30	28.30	28.30
Fixed assets	297.56	433.44	453.86	471.67	490.79	506.59	517.74
Inventories	1.09	1.51	1.50	0.00	0.00	0.00	0.00
Accounts receivable	63.07	75.20	83.03	84.70	80.70	91.30	103.00
Liquid assets	24.89	33.51	48.92	87.66	72.60	65.66	78.36
Other short-term assets	4.97	8.39	8.45	8.45	8.45	8.45	8.45
Current assets	94.02	118.61	141.91	180.81	161.75	165.42	189.82
Total Assets	391.60	552.00	595.80	652.50	652.50	672.00	707.60
Liabilities and shareholders' equity							
Subscribed capital	6.49	6.49	6.49	6.87	6.87	6.87	6.87
Capital reserve	51.11	65.77	66.93	116.55	116.55	116.55	116.55
Retained earnings	120.67	148.38	178.56	196.22	210.79	235.85	276.40
Other equity components	-0.24	-0.19	-0.19	-0.19	-0.19	-0.19	-0.19
Shareholders' equity	178.03	220.46	251.78	319.45	334.02	359.08	399.63
Minority interest	0.34	0.94	1.65	1.65	1.65	1.65	1.65
Total equity	178.38	221.39	253.43	321.10	335.67	360.73	401.28
Provisions	0.92	0.74	0.62	0.62	0.62	0.62	0.62
thereof provisions for pensions and similar obligations	0.92	0.74	0.62	0.62	0.62	0.62	0.62
Financial liabilities (total)	114.87	189.66	197.41	185.41	173.41	161.41	149.41
Short-term financial liabilities	16.41	14.02	16.11	16.11	16.11	16.11	16.11
Accounts payable	39.58	46.94	49.66	50.70	48.20	54.60	61.60
Other liabilities	57.84	93.31	94.65	94.65	94.65	94.65	94.65
Liabilities	213.20	330.66	342.34	331.38	316.88	311.28	306.28
Total liabilities and shareholders' equity	391.60	552.00	595.80	652.50	652.50	672.00	707.60

Financial Ratios

	2019	2020	2021	2022	2023e	2024e	2025e
Efficiency of Capital Employment							
Operating Assets Turnover	5.7 x	3.0 x	3.3 x	3.3 x	3.0 x	3.3 x	3.5 x
Capital Employed Turnover	1.3 x	1.0 x	1.1 x	1.1 x	1.0 x	1.1 x	1.2 x
ROA	8.2 %	6.3 %	6.6 %	3.7 %	3.0 %	4.9 %	7.8 %
Return on Capital							
ROCE (NOPAT)	10.9 %	9.3 %	8.4 %	4.7 %	3.8 %	6.0 %	9.1 %
ROE	14.7 %	13.7 %	12.8 %	6.2 %	4.5 %	7.2 %	10.7 %
Adj. ROE	14.7 %	13.7 %	12.8 %	6.2 %	4.5 %	7.2 %	10.7 %
Balance sheet quality							
Net Debt	90.89	156.89	149.11	98.37	101.43	96.37	71.67
Net Financial Debt	89.98	156.15	148.49	97.76	100.81	95.75	71.05
Net Gearing	51.0 %	70.9 %	58.8 %	30.6 %	30.2 %	26.7 %	17.9 %
Net Fin. Debt / EBITDA	172.3 %	244.6 %	192.6 %	188.3 %	216.3 %	151.0 %	80.8 %
Book Value / Share	28.5	35.3	40.3	51.1	50.4	54.2	60.3
Book value per share ex intangibles	-11.2	-13.8	-11.4	-2.7	-2.6	-0.7	4.0



COMMENT

Published 20.06.2023

6

Consolidated cash flow statement




	0040		0004		0000-	0004-	0005-
In EUR m	2019	2020	2021	2022	2023e	2024e	2025e
Net income	24.40	27.86	30.58	17.67	14.57	25.06	40.55
Depreciation of fixed assets	9.69	14.70	13.49	10.88	10.35	11.68	13.54
Amortisation of goodwill	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Amortisation of intangible assets	9.52	12.92	15.93	16.32	15.53	17.52	20.31
Increase/decrease in long-term provisions	0.63	-0.18	-0.12	0.00	0.00	0.00	0.00
Other non-cash income and expenses	0.00	-3.25	4.70	0.00	0.00	0.00	0.00
Cash Flow before NWC change	44.24	52.04	64.57	44.86	40.44	54.26	74.40
Increase / decrease in inventory	-0.31	-0.42	0.01	1.50	0.00	0.00	0.00
Increase / decrease in accounts receivable	-8.85	-12.13	-7.83	-1.67	4.00	-10.60	-11.70
Increase / decrease in accounts payable	7.59	7.36	2.72	1.04	-2.50	6.40	7.00
Increase / decrease in other working capital positions	3.53	-0.30	4.88	0.00	0.00	0.00	0.00
Increase / decrease in working capital (total)	1.97	-5.49	-0.22	0.87	1.50	-4.20	-4.70
Net cash provided by operating activities [1]	46.21	46.55	64.35	45.73	41.94	50.06	69.70
Investments in intangible assets	-27.02	-27.10	-30.02	-30.00	-30.00	-30.00	-30.00
Investments in property, plant and equipment	0.00	-77.36	-17.81	-15.00	-15.00	-15.00	-15.00
Payments for acquisitions	-33.04	-22.90	-7.17	0.00	0.00	0.00	0.00
Financial investments	0.02	0.02	0.92	0.00	0.00	0.00	0.00
Income from asset disposals	0.20	0.05	0.53	0.00	0.00	0.00	0.00
Net cash provided by investing activities [2]	-59.88	-59.51	-44.71	-45.00	-45.00	-45.00	-45.00
Change in financial liabilities	23.50	7.04	-4.23	-12.00	-12.00	-12.00	-12.00
Dividends paid	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Purchase of own shares	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Capital measures	0.00	14.54	0.00	50.00	0.00	0.00	0.00
Other	-16.72	0.00	0.00	0.00	0.00	0.00	0.00
Net cash provided by financing activities [3]	6.78	21.57	-4.23	38.00	-12.00	-12.00	-12.00
Change in liquid funds [1]+[2]+[3]	-6.90	8.62	15.41	38.73	-15.06	-6.94	12.70
Effects of exchange-rate changes on cash	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash and cash equivalent at end of period	24.86	33.51	48.92	87.66	72.60	65.66	78.36

Financial Ratios

	0040		0004				
	2019	2020	2021	2022	2023e	2024e	2025e
Cash Flow							
FCF	19.19	9.92	27.20	0.73	-3.06	5.06	24.70
Free Cash Flow / Sales	5.7 %	2.6 %	6.1 %	0.2 %	-0.7 %	1.0 %	4.5 %
Free Cash Flow Potential	45.18	58.31	63.42	46.86	42.44	56.26	76.40
Free Cash Flow / Net Profit	78.6 %	36.4 %	90.2 %	4.2 %	-21.0 %	20.2 %	60.9 %
Interest Received / Avg. Cash	1.8 %	0.8 %	0.4 %	1.2 %	1.0 %	1.2 %	1.1 %
Interest Paid / Avg. Debt	2.1 %	2.0 %	1.9 %	1.6 %	1.7 %	1.8 %	1.9 %
Management of Funds							
Investment ratio	8.0 %	26.9 %	10.7 %	9.9 %	10.4 %	9.2 %	8.1 %
Maint. Capex / Sales	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %
Capex / Dep	140.7 %	378.4 %	162.5 %	165.5 %	173.9 %	154.1 %	132.9 %
Avg. Working Capital / Sales	7.1 %	7.0 %	7.2 %	7.6 %	7.7 %	7.1 %	7.1 %
Trade Debtors / Trade Creditors	159.3 %	160.2 %	167.2 %	167.1 %	167.4 %	167.2 %	167.2 %
Inventory Turnover	142.9 x	117.4 x	131.4 x	n.a.	n.a.	n.a.	n.a.
Receivables collection period (days)	68	71	68	68	68	68	68
Payables payment period (days)	93	97	92	86	86	88	91
Cash conversion cycle (Days)	-22	-23	-21	n.a.	n.a.	n.a.	n.a.

CAPEX and Cash Flow in EUR m



Free Cash Flow Generation

7

Working Capital



LEGAL DISCLAIMER

This research report ("investment recommendation") was prepared by the Warburg Research GmbH, a fully owned subsidiary of the M.M.Warburg & CO (AG & Co.) KGaA and is passed on by the M.M.Warburg & CO (AG & Co.) KGaA. It is intended solely for the recipient and may not be passed on to another company without their prior consent, regardless of whether the company is part of the same corporation or not. It contains selected information and does not purport to be complete. The investment recommendation is based on publicly available information and data ("information") believed to be accurate and complete. Warburg Research GmbH neither examines the information for accuracy and completeness, nor guarantees its accuracy and completeness. Possible errors or incompleteness of the information do not constitute grounds for liability of M.M.Warburg & CO (AG & Co.) KGaA or Warburg Research GmbH for damages of any kind whatsoever, and M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are not liable for indirect and/or direct and/or consequential damages. In particular, neither M.M.Warburg & CO (AG & Co.) KGaA nor Warburg Research GmbH are liable for the statements, plans or other details contained in these investment recommendations concerning the examined companies, their affiliated companies, strategies, economic situations, market and competitive situations, regulatory environment, etc. Although due care has been taken in compiling this investment recommendation, it cannot be excluded that it is incomplete or contains errors. M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH, their shareholders and employees are not liable for the accuracy and completeness of the statements, estimations and the conclusions derived from the information contained in this investment recommendation. Provided a investment recommendation is being transmitted in connection with an existing contractual relationship, i.e. financial advisory or similar services, the liability of M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH shall be restricted to gross negligence and wilful misconduct. In case of failure in essential tasks, M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are liable for normal negligence. In any case, the liability of M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH is limited to typical, expectable damages. This investment recommendation does not constitute an offer or a solicitation of an offer for the purchase or sale of any security. Partners, directors or employees of M.M.Warburg & CO (AG & Co.) KGaA, Warburg Research GmbH or affiliated companies may serve in a position of responsibility, i.e. on the board of directors of companies mentioned in the report. Opinions expressed in this investment recommendation are subject to change without notice. The views expressed in this research report accurately reflect the research analyst's personal views about the subject securities and issuers. Unless otherwise specified in the research report, no part of the research analyst's compensation was, is, or will be directly or indirectly related to the specific recommendations or views contained in the research report. All rights reserved.

COPYRIGHT NOTICE

This work including all its parts is protected by copyright. Any use beyond the limits provided by copyright law without permission is prohibited and punishable. This applies, in particular, to reproductions, translations, microfilming, and storage and processing on electronic media of the entire content or parts thereof.

DISCLOSURE ACCORDING TO §85 OF THE GERMAN SECURITIES TRADING ACT (WPHG), MAR AND MIFID II INCL. COMMISSION DELEGATED REGULATION (EU) 2016/958 AND (EU) 2017/565

The valuation underlying the investment recommendation for the company analysed here is based on generally accepted and widely used methods of fundamental analysis, such as e.g. DCF Model, Free Cash Flow Value Potential, NAV, Peer Group Comparison or Sum of the Parts Model (see also <u>http://www.mmwarburg.de/disclaimer/disclaimer.htm#Valuation</u>). The result of this fundamental valuation is modified to take into consideration the analyst's assessment as regards the expected development of investor sentiment and its impact on the share price.

Independent of the applied valuation methods, there is the risk that the price target will not be met, for instance because of unforeseen changes in demand for the company's products, changes in management, technology, economic development, interest rate development, operating and/or material costs, competitive pressure, supervisory law, exchange rate, tax rate etc. For investments in foreign markets and instruments there are further risks, generally based on exchange rate changes or changes in political and social conditions.

This commentary reflects the opinion of the relevant author at the point in time of its compilation. A change in the fundamental factors underlying the valuation can mean that the valuation is subsequently no longer accurate. Whether, or in what time frame, an update of this commentary follows is not determined in advance.

Additional internal and organisational arrangements to prevent or to deal with conflicts of interest have been implemented. Among these are the spatial separation of Warburg Research GmbH from M.M.Warburg & CO (AG & Co.) KGaA and the creation of areas of confidentiality. This prevents the exchange of information, which could form the basis of conflicts of interest for Warburg Research GmbH in terms of the analysed issuers or their financial instruments.

The analysts of Warburg Research GmbH do not receive a gratuity – directly or indirectly – from the investment banking activities of M.M.Warburg & CO (AG & Co.) KGaA or of any company within the Warburg-Group.

All prices of financial instruments given in this investment recommendation are the closing prices on the last stock-market trading day before the publication date stated, unless another point in time is explicitly stated.

M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are subject to the supervision of the Federal Financial Supervisory Authority, BaFin. M.M.Warburg & CO (AG & Co.) KGaA is additionally subject to the supervision of the European Central Bank (ECB).

SOURCES

All data and consensus estimates have been obtained from FactSet except where stated otherwise.

The **Warburg ESG Risk Score** is based on information © 2020 MSCI ESG Research LLC. Reproduced by permission. Although Warburg Research's information providers, including without limitation, MSCI ESG Research LLC and its affiliates (the "ESG Parties"), obtain information (the "Information") from sources they consider reliable, none of the ESG Parties warrants or guarantees the originality, accuracy and/or completeness, of any data herein and expressly disclaim all express or implied warranties, including those of merchantability and fitness for a particular purpose. The Information may only be used for your internal use, may not be reproduced or redisseminated in any form and may not be used as a basis for, or a component, of any financial instruments or products indices. Further, none of the Information can in and of itself be used to determine which securities to buy or sell or when to buy or sell them. None of the ESG Parties shall have any liability for any errors or omissions in connection with any data herein, or any liability for any direct, indirect, special, punitive, consequential or any other damage (including lost profits) even if notified of the possibility.



Additional information for clients in the United States

1. This research report (the "Report") is a product of Warburg Research GmbH, Germany, a fully owned subsidiary of M.M.Warburg & CO (AG & Co.) KGaA, Germany (in the following collectively "Warburg"). Warburg is the employer of the research analyst(s), who have prepared the Report. The research analyst(s) reside outside the United States and are not associated persons of any U.S. regulated broker-dealer and therefore are not subject to the supervision of any U.S. regulated broker-dealer.

2. The Report is provided in the United States for distribution solely to "major U.S. institutional investors" under Rule 15a-6 of the U.S. Securities Exchange Act of 1934 by CIC.

3. CIC (Crédit Industriel et Commercial) and M.M. Warburg & CO have concluded a Research Distribution Agreement that gives CIC Market Solutions exclusive distribution in France, the US and Canada of the Warburg Research GmbH research product.

4. The research reports are distributed in the United States of America by CIC ("CIC") pursuant to a SEC Rule 15a-6 agreement with CIC Market Solutions Inc ("CICI"), a U.S. registered broker-dealer and a related company of CIC, and are distributed solely to persons who qualify as "Major U.S. Institutional Investors" as defined in SEC Rule 15a-6 under the Securities Exchange Act of 1934.

5. Any person who is not a Major U.S. Institutional Investor must not rely on this communication. The delivery of this research report to any person in the United States of America is not a recommendation to effect any transactions in the securities discussed herein, or an endorsement of any opinion expressed herein.

Reference in accordance with section 85 of the German Securities Trading Act (WpHG) and Art. 20 MAR regarding possible conflicts of interest with companies analysed:

- -1- Warburg Research, or an affiliated company, or an employee of one of these companies responsible for the compilation of the research, hold a share of more than 5% of the equity capital of the analysed company.
- -2- Warburg Research, or an affiliated company, within the last twelve months participated in the **management of a consortium** for an issue in the course of a public offering of such financial instruments, which are, or the issuer of which is, the subject of the investment recommendation.
- -3- Companies affiliated with Warburg Research manage financial instruments, which are, or the issuers of which are, subject of the investment recommendation, in a market based on the provision of buy or sell contracts.
- MMWB, Warburg Research, or an affiliated company, reached an agreement with the issuer to provide investment banking and/or investment services and the relevant agreement was in force in the last 12 months or there arose for this period, based on the relevant agreement, the obligation to provide or to receive a service or compensation provided that this disclosure does not result in the disclosure of confidential business information.
- -5- The company compiling the analysis or an affiliated company had reached an **agreement on the compilation of the investment recommendation** with the analysed company.
- -6a- Warburg Research, or an affiliated company, holds a **net long position of more than 0.5%** of the total issued share capital of the analysed company.
- -6b- Warburg Research, or an affiliated company, holds a **net short position of more than 0.5%** of the total issued share capital of the analysed company.
- -6c- The issuer holds shares of more than 5% of the total issued capital of Warburg Research or an affiliated company.
- -7- The company preparing the analysis as well as its affiliated companies and employees have **other important interests** in relation to the analysed company, such as, for example, the exercising of mandates at analysed companies.

Company	Disclosure	Link to the historical price targets and rating changes (last 12 months)
HYPOPORT	5	https://www.mmwarburg.com/disclaimer/disclaimer en/DE0005493365.htm



INVESTMENT RECOMMENDATION

Investment recommendation: expected direction of the share price development of the financial instrument up to the given <u>price target</u> in the opinion of the analyst who covers this financial instrument.

-B-	Buy: The price of the analysed financial instrument is expected to rise over the next 12 months.		
-H-	Hold:	The price of the analysed financial instrument is expected to remain mostly flat over the next 12 months.	
-S-	Sell:	The price of the analysed financial instrument is expected to fall over the next 12 months.	
"_"	Rating suspended:	The available information currently does not permit an evaluation of the company.	

WARBURG RESEARCH GMBH - ANALYSED RESEARCH UNIVERSE BY RATING

Rating	Number of stocks	% of Universe
Buy	159	75
Hold	43	20
Sell	7	3
Rating suspended	3	1
Total	212	100

WARBURG RESEARCH GMBH - ANALYSED RESEARCH UNIVERSE BY RATING ...

... taking into account only those companies which were provided with major investment services in the last twelve months.

Rating	Number of stocks	% of Universe
Buy	45	88
Hold	5	10
Sell	0	0
Rating suspended	1	2
Total	51	100

PRICE AND RATING HISTORY HYPOPORT AS OF 20.06.2023



Markings in the chart show rating changes by Warburg Research GmbH in the last 12 months. Every marking details the date and closing price on the day of the rating change.

EQUITIES

Matthias Rode Head of Equities

RESEARCH

Michael Heider Head of Research Henner Rüschmeier Head of Research Stefan Augustin Cap. Goods, Engineering Jan Bauer Renewables **Christian Cohrs** Industrials & Transportation Dr. Christian Ehmann BioTech, Life Science Felix Ellmann Software, IT Jörg Philipp Frey Retail. Consumer Goods Marius Fuhrberg Financial Services Fabio Hölscher Automobiles. Car Suppliers Philipp Kaiser Real Estate, Construction Thilo Kleibauer Retail Consumer Goods

INSTITUTIONAL EQUITY SALES

+49 40 309537-280 mheider@warburg-research.com +49 40 309537-270 hrueschmeier@warburg-research.com +49 40 309537-168 saugustin@warburg-research.com +49 40 309537-155 jbauer@warburg-research.com +49 40 309537-175 ccohrs@warburg-research.com +49 40 309537-167 cehmann@warburg-research.com +49 40 309537-120 fellmann@warburg-research.com +49 40 309537-258 jfrey@warburg-research.com +49 40 309537-185 mfuhrberg@warburg-research.com +49 40 309537-240 fhoelscher@warburg-research.com +49 40 309537-260 pkaiser@warburg-research.com +49 40 309537-257 tkleibauer@warburg-research.com

+49 40 3282-2678

mrode@mmwarburg.com

+49 40 3282-2660 mniemann@mmwarburg.com +49 69 5050-7400 kschilling@mmwarburg.com +49 40 3282-2665 tbeckmann@mmwarburg.com +49 69 5050-7411 lbogdanova@mmwarburg.com +49 69 5050-7415 jbuchmueller@mmwarburg.com +49 40 3282-2696 mfritsch@mmwarburg.com +49 69 5050-7413 mmartin@mmwarburg.com

SALES TRADING

Maximilian Martin

Marc Niemann

Klaus Schilling

Tim Beckmann

Lea Bogdanova

Jens Buchmüller

Scandinavia, Austria

Matthias Fritsch

United Kingdom

Austria. Poland

United Kingdom, Ireland

United Kingdom

Head of Equity Sales. Germany

Head of Equity Sales, Germany

+49 40 3282-2634 **Oliver Merckel** Head of Sales Trading omerckel@mmwarburg.com Marcel Magiera +49 40 3282-2662 Sales Trading mmagiera@mmwarburg.com Rico Müller +49 40 3282-2685 Sales Trading rmueller@mmwarburg.com **Bastian Quast** +49 40 3282-2701 Sales Trading bquast@mmwarburg.com

MACRO RESEARCH

Carsten Klude +49 40 3282-2572 Dr. Christian Jasperneite +49 40 3282-2439 Macro Research cklude@mmwarburg.com Investment Strategy cjasperneite@mmwarburg.com Our research can be found under: Warburg Research research.mmwarburg.com/en/index.html Refinitiv www.refinitiv.com Bloomberg **RESP MMWA GO** Capital IQ www.capitaliq.com FactSet www.factset.com For access please contact: Andrea Schaper +49 40 3282-2632 **Kerstin Muthig** +49 40 3282-2703 Sales Assistance aschaper@mmwarburg.com Sales Assistance kmuthig@mmwarburg.com

> 11 COMMENT Published 20.06.2023



Hannes Müller Software, I Andreas Pläsier Banks, Financial Services Malte Schaumann Technology **Oliver Schwarz** Chemicals, Agriculture Simon Stippig Real Estate. Telco Cansu Tatar Cap. Goods, Engineering Marc-René Tonn Automobiles, Car Suppliers Robert-Jan van der Horst Technology Andreas Wolf Software, IT

+49 40 309537-255 hmueller@warburg-research.com +49 40 309537-246 aplaesier@warburg-research.com +49 40 309537-170 mschaumann@warburg-research.com +49 40 309537-250 oschwarz@warburg-research.com +49 40 309537-265 sstippig@warburg-research.com +49 40 309537-248 ctatar@warburg-research.com +49 40 309537-259 mtonn@warburg-research.com +49 40 309537-290 rvanderhorst@warburg-research.com +49 40 309537-140 awolf@warburg-research.com

Rudolf Michaelis Switzerland **Christopher Seedorf** Switzerland

Charlotte Wernicke Roadshow/Marketing Juliane Niemann Roadshow/Marketing

Jan-Philip Schmidt Sales Trading Sebastian Schulz Sales Trading Jörg Treptow Sales Trading

+49 40 3282-2669 cwernicke@mmwarburg.com +49 40 3282-2694 jniemann@mmwarburg.com

+49 40 3282-2649

+49 40 3282-2695

rmichaelis@mmwarburg.com

cseedorf@mmwarburg.com

+49 40 3282-2682 jschmidt@mmwarburg.com +49 40 3282-2631 sschulz@mmwarburg.com +49 40 3282-2658 jtreptow@mmwarburg.com